United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Covid vaccine developer BioNTech is to take a write-down of up to €900 million on its stocks of jabs following a similar provision by partner Pfizer last week. Pfizer had said that the write-offs relate to raw materials purchased during the pandemic, as well as Covid-19 vaccine doses adapted to non-XBB.1.5 variants.

Pfizer and BioNtech take big write-downs on Covid jab stocks

Moderna

Hubbell

Lululemon Athletica

Manchester United

Novavax

Shares of Lululemon Athletica Inc. LULU, +1.00% rallied more than 5% after index provider S&P Dow Jones Indices said the stock will join the S&P 500 index SPX on Wednesday.

Pfizer shares fall on guidance cut, weighing on BioNTech and Moderna stocks, and other shares on the move

In 2021, Pfizer‘s (NYSE: PFE) shares skyrocketed as the pharmaceutical giant dominated the vaccine industry with its launch of the COVID-19 jab, more than doubling in value and reporting a staggering $37 billion in vaccine sales.

Pfizer stock erases all Covid gains; Should you still buy PFE?

Germany's BioNTech on Monday said it would likely take write-downs of up to 900 million euros ($947 million) in the third quarter after its partner Pfizer reported similar charges on their COVID-19 vaccine business last week.

BioNTech will likely take 900 mln eur write-off on Pfizer-partnered vaccines

Pfizer is focusing on its core growth engines and strategic acquisitions, particularly in the oncology segment, to compensate for downgraded revenue projections and a concerning debt profile. The company's financial health is fragile, with a significant decrease in FY23 revenue and EPS outlook and a high total debt-to-liquid assets ratio. Market sentiment towards Pfizer is cautious, with modest growth expectations and underperformance compared to the broader market, but limited investor pessimism and a commitment to returning capital to shareholders through dividends.

Pfizer's Sequel: Return Of The Value Stock

SHANGHAI , Oct. 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administration (FDA) for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC). Importantly, VELSIPITY™'s label does not include the "titration is required for treatment initiation" language found in other S1P modulator's label.

Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis

Data include three late-breaking abstracts, underscoring Astellas' efforts to potentially redefine expectations for patients across its oncology portfolio TOKYO , Oct. 15, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research results during the European Society for Medical Oncology (ESMO) Congress 2023 from October 20-24, showcasing the company's focus on making a meaningful difference for people living with hard-to-treat cancers. A total of 13 abstracts will be presented, highlighting data from two established medicines and one investigational therapy, across prostate, urothelial, and gastric/gastroesophageal junction (GEJ) cancers.

Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023

Gilead Sciences

Pfizer is on a roll of important approvals that will eventually fill the gap left by its coronavirus portfolio. Gilead Sciences has a deep lineup and pipeline that are especially concentrated around HIV and oncology.

2 Dirt Cheap High-Yield Dividend Stocks to Buy Right Now

Combining sustainable income and deep value is an investing strategy that can work very well over the long run. Pfizer's market-smashing dividend is comfortably covered by its adjusted diluted EPS. The pharmaceutical has the product portfolio and pipeline needed to stage a recovery in its business.

Pfizer: Buy This Big Pharma Stock For Safe Income And Deep Value

The pharmaceutical company warned in January it expected revenue for its Covid vaccine and Paxlovid pill to drop sharply.

Pfizer Launches $3.5 Billion Cost-Cutting Program Amid Declining Covid Vaccine Sales

Pfizer said it anticipates sales of its Covid treatment Paxlovid and its vaccine will be $9 billion less than it had expected.

Pfizer slashes full-year earnings and revenue guidance as Covid treatment, vaccine sales slump

Pfizer on Friday slashed its full-year revenue forecast by around 13% and launched a $3.5 billion cost cutting program due to lower-than-expected sales of its COVID-19 vaccine and treatment.

Pfizer slashes 2023 revenue forecast on lower COVID sales; will cut expenses, jobs

Pfizer Inc. PFE, -2.46% shares dropped in the extended session Friday after the drug maker slashed its full-year outlook due to COVID product write offs. Pfizer shares dropped more than 7% after hours, following a 2.5% decline to close the regular session at $32.11.

Pfizer's stock sinks after company cuts outlook on lower demand for COVID products

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has amended its supply agreement with the U.S. government for Paxlovid, the first oral antiviral pill approved by the U.S. Food and Drug Administration (FDA) and is updating its Full-Year 2023 Guidance. Paxlovid Amended Agreement with U.S. Government Facilitates Commercialization At the end of 2023, Pfizer will accept a non-cash return of any remaining Emergency Use Authorized (EUA)-labeled U.S. government inventory, esti.

Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance

Pfizer's (PFE) Braftovi + Mektovi drug combo gets label expansion for BRAF V600E-mutant non-small cell lung cancer.

FDA Approves Pfizer's (PFE) Braftovi + Mektovi for Lung Cancer

Pfizer said on Friday that theU.S. Food and Drug Administration has approved its drug to treat adults with moderate-to-severe inflammatory bowel disease, ulcerative colitis.

U.S. FDA approves Pfizer's inflammatory bowel disease drug

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC). The approved recommended dose for VELSIPITY is 2 mg. UC is a chronic and often debilitating condition1 that affects an estimated 1.25 million people in the United States.2 Symptoms of UC can incl.

U.S. FDA Approves Pfizer's VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)

The European Union medicines regulator on Friday recommended a conditional marketing authorization for U.S. drugmaker Pfizer's therapy for a type of blood cancer that is difficult to treat.

EU regulator backs Pfizer's blood cancer therapy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--FDA approves FoundationOne®CDx and FoundationOne®Liquid CDx as companion diagnostics for Pfizer's BRAFTOVI® (encorafenib) in combination with MEKTOVI®.

FDA Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Pfizer's BRAFTOVI® (encorafenib) in Combination With MEKTOVI® (binimetinib) to Identify Patients with BRAF V600E Alterations in Metastatic NSCLC

Strive US Energy ETF

Fidelity MSCI Energy Index ETF

iShares U.S. Oil & Gas Exploration & Production ETF

iShares U.S. Energy ETF

Pioneer Natural Resources

Energy Select Sector SPDR Fund

Exxon Mobil

The largest U.S. oil producer, Exxon Mobil Corp. (XOM) has agreed to acquire Pioneer Natural Resources (PXD) in an all-stock deal valued at $59.5 billion or $253 per share.

ETFs to Benefit From the Historic Exxon-Pioneer Oil Merger

Adobe

AstraZeneca

Chevron

UnitedHealth Group

UnitedHealth, Chevron, AstraZeneca, Adobe and Pfizer are part of the Zacks Analyst Blog.

The Zacks Analyst Blog UnitedHealth, Chevron, AstraZeneca, Adobe and Pfizer

Pfizer Inc (NYSE:PFE) announced that the United States Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) plus MEKTOVI (binimetinib) for adult patients with metastatic non-small cell lung cancer, as detected by an FDA-approved test. The pharmaceutical giant said the approval is based on data from its ongoing Phase 2 PHAROS trial which is examining BRAFTOVI plus MEKTOVI combination therapy in both treatment-naïve and previously treated patients with BRAF V600E-mutant metastatic non-small cell lung cancer.

Pfizer's lung cancer combination therapy approved by the FDA

Pfizer Inc. PFE, -0.18% said Thursday the U.S. Food and Drug Administration has approved its Braftovi plus Mektovi combination therapy as a treatment for patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. That mutation can be assessed from plasma or tumor tissue using an FDA-approved test.

FDA approves Pfizer's Braftovi plus Mektovi for a type of non-small cell lung cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.1 BRAF V600E mutations can be assessed from either plasma or tumor tissue using the FoundationOne Liquid CDx or the FoundationOne CDx FDA-approved companion diagnostic te.

U.S. FDA Approves Pfizer's BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

AllianceBernstein Hld

Arbor Realty Trust

American Tower

Ares Capital

Alexandria Real Estate Equities

BHP Billiton

British American Tobacco

Fifth Third Bancorp

Hasbro

Navient

NexPoint Residential Trust

March-April, 2022, UBS, Kiplinger, and Barron's analysts/reporters listed five-sets of stocks sorted as: “Inflation Busters.” Those five articles revealed 48 equities, with 43 paying dividends. This 1.5-year-old-list continues to beat-back the inflation-zombie.

News for Pfizer Stock (PFE)